• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Legend Biotech Corporation

    2/5/26 1:28:06 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LEGN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    LEGEND BIOTECH CORP

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    52490G102

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    52490G102


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    48,202,106.24
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    48,294,445.48
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    48,294,445.48
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    13.1 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    52490G102


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    48,294,445.48
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    48,294,445.48
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    13.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    LEGEND BIOTECH CORP
    (b)Address of issuer's principal executive offices:

    2101 COTTONTAIL LANE,SOMERSET,NJ,USA,08873
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    52490G102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    48294445.48
    (b)Percent of class:

    13.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    48294445.48

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares of LEGEND BIOTECH CORP. No one other person's interest in the Ordinary Shares of LEGEND BIOTECH CORP is more than five percent of the total outstanding Ordinary Shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:02/04/2026
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:02/04/2026

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $LEGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LEGN

    DatePrice TargetRatingAnalyst
    2/12/2026$24.00Buy → Neutral
    Rothschild & Co Redburn
    1/22/2026$21.00Buy → Hold
    TD Cowen
    1/7/2026$75.00Outperform
    Oppenheimer
    10/7/2025$40.00Overweight
    Cantor Fitzgerald
    10/8/2024$86.00Buy
    Redburn Atlantic
    6/17/2024$88.00Buy
    Truist
    5/24/2024$86.00 → $73.00Buy
    H.C. Wainwright
    5/23/2024$60.00Buy
    Deutsche Bank
    More analyst ratings

    $LEGN
    SEC Filings

    View All

    SEC Form 6-K filed by Legend Biotech Corporation

    6-K - Legend Biotech Corp (0001801198) (Filer)

    6/2/26 9:30:03 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Legend Biotech Corporation

    6-K - Legend Biotech Corp (0001801198) (Filer)

    6/1/26 10:00:03 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Legend Biotech Corporation

    6-K - Legend Biotech Corp (0001801198) (Filer)

    5/21/26 5:00:04 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

    Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignanciesAn ORR of 100% (6/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5/6) in patients with relapsed/ refractory NHLData demonstrate robust in vivo CAR-T expansion without lymphodepleting chemotherapy Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS <Grade 2 BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501,

    6/2/26 9:30:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

    LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of 78.6%, with durable responses seen in some patients New CARVYKTI® data continue to support durable efficacy and a consistent safety profile in multiple myeloma BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) --  Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small

    6/1/26 10:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

    CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 millionCARVYKTI® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and AustraliaAdvanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026Cash and cash equivalents, and time deposits of $834.6 million, as of March 31, 2026. SOMERSET, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2026 unaudited financial results and key corporate highl

    5/12/26 7:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Legend Biotech downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Legend Biotech from Buy to Neutral and set a new price target of $24.00

    2/12/26 7:23:25 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech downgraded by TD Cowen with a new price target

    TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00

    1/22/26 8:26:15 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Legend Biotech with a new price target

    Oppenheimer initiated coverage of Legend Biotech with a rating of Outperform and set a new price target of $75.00

    1/7/26 8:37:12 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Huang Ying

    4 - Legend Biotech Corp (0001801198) (Issuer)

    3/27/26 4:25:51 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Heyman Tomas J.

    3 - Legend Biotech Corp (0001801198) (Issuer)

    3/18/26 7:04:43 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Meng Robin

    3 - Legend Biotech Corp (0001801198) (Issuer)

    3/18/26 7:02:50 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Financials

    Live finance-specific insights

    View All

    Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

    CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 millionCARVYKTI® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and AustraliaAdvanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026Cash and cash equivalents, and time deposits of $834.6 million, as of March 31, 2026. SOMERSET, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2026 unaudited financial results and key corporate highl

    5/12/26 7:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

    SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentation approximately two hours

    4/28/26 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

    CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients treated with CARVYKTI®CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settingsAdvanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN)

    3/10/26 7:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Leadership Updates

    Live Leadership Updates

    View All

    Legend Biotech Appoints Carlos Santos as Chief Financial Officer

    SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025. Mr. Santos is a seasoned finance executive who has led financial operations in the pharmaceutical and technology sectors across the United States, Latin America, Europe, the Middle East, and Africa. At Legend, he will oversee financial operations to work to ensure a robust balance sheet and achieve and maintain profitability. "On behalf

    8/18/25 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech Appoints Alan Bash as President of CARVYKTI®

    SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg

    11/4/24 7:30:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

    SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. "This new facility underscores Legend's commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partn

    10/3/24 7:30:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

    SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

    11/14/24 1:22:39 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

    SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

    11/12/24 10:32:10 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Legend Biotech Corporation (Amendment)

    SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

    4/5/24 12:18:27 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care